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Src-family kinases (SFKs) play important roles in human biology and are key drug targets as well.
However, achieving selective inhibition of individual Src-family kinases is challenging due to the high
similarity within the protein family. We describe rhodium(II) conjugates that deliver both potent and
selective inhibition of Src-family SH3 domains. Rhodium(II) conjugates offer dramatic affinity
enhancements due to interactions with specific and unique Lewis-basic histidine residues near the SH3
binding interface, allowing predictable, structure-guided inhibition of SH3 targets that are recalcitrant to
traditional inhibitors. In one example, a simple metallopeptide binds the Lyn SH3 domain with 6-nM affinity
and exhibits functional activation of Lyn kinase under biologically relevant concentrations (EC50 ~200 nM).

Introduction
The Src-family SH3 domains are functionally important
mediators of protein assembly and of signaling pathways that
illustrate the problems of “undruggable” targets. SH3 domains
are ubiquitous and versatile subunits, appearing ~300 times in
the human genome in proteins implicated in the proliferation of
cancer and other diseases. The domains recognize short,
proline-rich motifs (e.g. PxxP). However, our ability to
chemically perturb Src-family SH3 interactions in a selective
way is limited: SH3 domain interactions are weak (Kd ~1-10
µM) interactions at a shallow binding interface and are highly
conserved, especially among protein families such as the Srcfamily kinases. The Lyn kinase is a prototypical Src-family
kinase. It contains a kinase domain and two regulatory
domains: an SH3 and an SH2, which are believed to be
involved in both upstream and downstream interactions. 1,2 It
shares significant sequence similarity with its Src-family
brethren. Lyn and Lck, for example, have 63% sequence
identity, similar to other comparisons within the family.
The SH3 domain represents an attractive and daunting
challenge for inhibitor development. Within the Src family and
in other related kinases, the catalytic kinase domain has been
the primary target of inhibitor development. However, because
the Src-family proteins have a high degree of similarity, kinase
inhibitors can display unacceptable off-target activity. Thus the
SH3 domain is a potentially powerful new target if truly
selective inhibitors can be developed. In addition, SH3selective inhibitors would shed light on kinase biology. The
relative roles that Lyn SH2 and SH3 interactions play in the
plethora of upstream and downstream signaling pathways
known for Src-family kinases are poorly understood, apart from
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limited reports.3,4 The development of domain- and proteinspecific tool compounds could untangle the roles SH3 domains
in kinase activation, catalytic reactivity, and substrate
preference. Efforts to inhibit SH3 interactions have met with
limited success, both in terms of potency and selectivity.
Peptides5,6 and peptoids7 similar to the natural target sequence
have been used in a variety of contexts to inhibit SH3
interactions, though IC50 ≥100 µM is typical. In one noteworthy
approach, macromolecular, divalent ligands that bind
simultaneously to SH3 and SH2 domains have been used to
deliver increased potency. 8,9 However, selectivity remains a
general challenge when targeting Src-family kinases or
members of other closely-related families.10 One small
molecule, reported to disrupt SH3 interactions, was later shown
to have no SH3 affinity.11-13 The Pyke group has reported 2aminoquinolines that bind the Tec SH3 (~10–100 µM), perhaps
the most effective small molecule inhibitors to date.14,15 The
HIV Nef protein binds tightly to the Hck SH3 domain, and
exhibits half-maximal activation of Hck at 130 nM, 14 though
Nef also displays promiscuous activation of several other Srcfamily kinases.16,17
Dirhodium conjugates have unique properties that make
them particularly well suited as inhibitors of specific protein–
protein interactions. Dirhodium conjugates can benefit from
metal–ligand interactions with histidine or other Lewis-basic
residues on the surface of the target protein near the binding
interface, offering potentially dramatic affinity benefits relative
to traditional noncovalent organic interactions, which are
typically weak. Dirhodium complexes are especially appealing
in this regard due to a differential coordination environment—
containing both exchange-inert equatorial sites that allow for
stable conjugation and also weakly-held axial ligands for
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dynamic sampling of Lewis basic residues. Dirhodium
complexes also have a history of biological and medical studies
that indicating compatibility with living systems. 18-23 The use of
transition metals for such Lewis-basic anchoring of ligand
molecules through specific interactions with the target protein
is not widely studied. We have demonstrated inhibition with
dirhodium cores in designed 24 and natural protein25,26 contexts,
and others have implemented similar ideas with cobalt 27,28 and
copper,29 for example. Designing metal coordination with
protein target residues contrasts with alternative approaches
that use transition metals as structural elements, 30,31 oxidative
damage agents,32 or cytotoxic species.33,34

Results and discussion

Journal Name
across Src-family SH3 domains,38 we made metallopeptides
with rhodium in different sites near the beginning of the SH3binding peptide. Several of these showed increased affinity
(Figure 1). The optimal metallopeptide, S2ERh, bound to Lyn
with 6-nM affinity. The accuracy of ITC data is reduced for C
values >1000 (C = [protein]/Kd). Under these conditions the
distribution of data points on the isotherm reduces the precision
of the global fit. Since the enthalpic contributions to binding in
the formation of the complexes described in this work were
high, we were able to use a low protein concentration (4 uM)
which ensured that our C values were well below this upper
range. (The highest C value in our work is ~670.) Isothermal
titration calorimetry (ITC) measurements revealed an enthalpydriven binding event (ΔH = -13.9 kcal mol-1) with a much
smaller entropic penalty for binding (–TΔS = 2.7 kcal mol-1) at
25 °C. In broad terms, the thermodynamics—favourable
enthalpy and unfavourably entropy—are consistent with
previous examinations of peptide–SH3 binding (see Table S1
for thermodynamic data). 39 Moving the location of the rhodium
center toward the N-terminus, away from the histidine, led to a
drop in binding affinity. The N13DRh metallopeptide, a
convenient negative control with the rhodium ceneter too far
for histidine interactions, binds with micromolar activity,
similar to simple SH3 binding of the parent peptide. We
concludethat the vast affinity improvement is due to rhodium
coordination to unique histidine residue(s). The Hck domain—
which shares one of two key histidine residues (Lyn His78; Hck
His93) with Lyn—also exhibited significant affinity (Kd 26 nM,
Table 1, entry 2) for the S2ERh metallopeptide. A
metallopeptide N13D Rh, which positions the rhodium center far
away from the Lyn His78 and His96 provided no affinity
enhancement relative to the parent peptide.

Figure 1. (a,b) Structures of the SH3 domains of representative Src-family
kinases, Lyn (PDB ID: 1W1F)35 and Lck (PDB ID: 2IIM)36 with a peptide ligand (PDB
ID: 4EIK). Histidine residues in the SH3 domain are shown explicitly. (c)
Alignment of core SH3 residues for a variety of human Src-family (1–7) and other
SH3 domains, highlighting histidine residues. (d) Affinity of designed rhodium(II)
metallopeptides for three Src-family SH3 domains.

Sequence and structure analysis shows that Lyn has two
non-conserved histidine residues near the top of its binding
pocket, His78 and His96 (Figure 1a). The His96 is unique
among Src-family sequences, and the His78 appears only in
Hck and Lck. Individual amino-acid alterations are the only
factors that might distinguish the nearly identical secondary
structures and peptide-binding preferences of Src-family SH3
domains (cf. Figure 1a, b). Based on a Src-family SH3-binding
sequence (VSL12),37 known to binds with similar affinity
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Figure 2. (a) Structure of the optimal Lyn-binding peptide, S2ERh. (b,c) ITC analysis
for affinity determination of S2ERh (b) and a negative control (c).
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The remarkable 6-nM affinity, far stronger than that of any
reported non-protein ligand for SH3 domains, led us to study
the structural basis of the observed affinity. Mutation
experiments prove that both His78 and His96, in the Lyn SH3
binding pocket, contribute to potent binding. The H78A and
H96A mutants bind to S2E Rh with 20- and 39-nM affinity,
respectively. The H78A and H96A double mutant binds much
more weakly (>5 µM). These results indicate that both histidine
residues bind to the dirhodium core, presumably by binding in a
co-linear fashion to each of the two rhodium atoms. The two
single-histidine mutants bind with roughly similar affinity, 3–7
fold less potent than the native Lyn, and ~100x more potent
than the parent peptide, implying that both histidines are well
positioned to coordinate to the dirhodium center. That the
majority of the stabilization energy comes from the first
histidine coordination is consistent with the negative
cooperativity generally seen for axial coordination to
rhodium(II): a second coordination in solution is roughly two
orders of magnitude less favorable. 40-43
Table 1. Affinity (Kd) of selected metallopeptides for various human SH3
domains.a
SH3 Kd (nM)
entry protein S2ERh L3ERh R6ERh N13DRh P12DRh
1

Lyn

6.1

2

Hck

26

b

3

Lck

481

4

Yes

610

3,745

301

5

Fyn

769

5,130

238

6

Src

327

7

Abl

5747

30
52

b

152

1,203

51

544

2315

3788

239

79

8,850

p40p40A1ERh Y4ERh

22

side chain of S2E replaced an equatorial acetate ligand in order
to position the peptide near the SH3 binding groove. Two-layer
ONIOM calculations were performed on Lyn-S2ERh isomers
using the DFT functional B3LYP for the QM layer and the
force field UFF for the MM layer. The most energetically stable
isomer is predicted to arise from bis-histidine binding through
both γ-nitrogen atoms.47 This binding motif also necessitates
the least displacement of the native Lyn structure (Figure S13).
In the optimized structure of the Nγ-Nγ isomer (Figure 3a), the
metallopeptide (yellow) overlays closely with a published
structure for an SH3-binding peptide (magenta) in the Cterminal region. At the extreme N-terminus, on the other hand,
the peptide backbone is displaced, and the short helical
structure of the canonical peptide structure is replaced by the
dirhodium core occupying the cleft between the two histidine
residues (Figure 3b). A slice depicting the histidine-containing
region of the reported Lyn SH3 structure (Figure 3c, yellow)
and the calculated Lyn structure bound to S2E Rh (green),
demonstrates what little backbone alterations are needed to
accommodate bis-histidine binding to the rhodium core. Based
on the model, only small conformational changes in the Glu95Trp99 and Ile77-Asp80 loops are required to position His78
and His96 to interact with the dirhodium tetraacetate, consistent
with the small entropic penalty for binding observed in the ITC
measurements.

7,194

a

All affinities measured by ITC. b ITC measurements with Hck contain a
second low-affinity (>20 µM) feature, presumably due to non-specific
histidine interactions. Abl-binding peptide (P40) = "p40": APTYSPPPPP.
P40-A1ERh = ERhPTYSPPPPP. P40-Y4ERh = APTERhSPPPPP. Fyn binding
data was previously reported (ref. 52).

The structure of the Lyn SH3 domain strongly suggests that
two histidine residues are well positioned to coordinate to a
dirhodium core, with the histidine side chains approaching from
different directions and coordinating separate rhodium atoms.
This bidentate trans coordination mode—reminiscent of
metalloproteins such as cytochrome C. 44—is rare in small
molecule ligands. We conducted a computational study using a
combination of molecular mechanics and quantum mechanics
to faithfully describe protein folding as well as rhodium
coordination. Specifically, previously determined structures of
Lyn (PDB ID: 1W1F) and Rh 2(OAc)445 were used as a starting
model for the metalloprotein. Four structural isomers based on
coordination of rhodium with His78 and His96 γ- and δnitrogen atoms were constructed. Geometry minimization was
carried out on the four initial structures using the UFF force
field in which the structural environment of Rh 2(OAc)4 and the
respective Rh-His bonds were frozen. 46 The Glu carboxylate

This journal is © The Royal Society of Chemistry 2012

Figure 3. Computational models of S2ERh bound to Lyn SH3. a) QM/MMoptimized structure of N-Nisomer of Lyn-S2ERh with overlayed native SH3binding peptide ligand (magenta). b) Depiction of the histidine flanked cleft of
LYN where dirhodium binding occurs. c) Top slice view of an overlay of native
LYN SH3 (yellow) and the N-Nisomer of Lyn-S2ERh (green). d) Overview of the
QM/MM optimization. High layer (DFT): tube. Low layer (MM): stick. See text
and ESI for details.

Rhodium(II) conjugation represents a general way to build
potent SH3 ligands in a predictable way from structural
information and simple design principles. Through a
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combination of sequence optimization and judicious choice of
rhodium location, it is possible to alter specificity to favor other
SH3 domains. Lck is another Src-family protein, with high
similarity to Lyn and possessing similarly SH3-binding-peptide
preferences.48 However, Lck lacks the Lyn His96 residue
(Figure 1), and does not bind tightly to S2E Rh (Figure 2). On the
other hand, Lck has a unique histidine (His70, see Figure 1b)
residue at the bottom of the pocket. By moving the rhodium
core to the 12th residue (P12D Rh), the affinity for Lck increased
to 79 nM as a consequence of specific interactions with the
unique His70 residue (Figure 2). Similarly, selective affinity for
a third Src-family member, Hck, could be achieved with the
R6ERh peptide (Table 1, entry 2), presumably due to
interactions with the unique His94 (homologous to Lyn 79)
found
in
Hck.
The
clean
formation
of
1:1
protein/metallopeptide complexes, even in the presence of
excess metallopeptide was also indicated by analytical FPLC
(see ESI).
An even more dramatic effect was observed with the Abl, a
kinase outside of the Src family. The Abl kinase, and its
constitutively active mutant variants, play key roles in tumor
growth, and Abl is an important protein in cancer biology and a
therapeutic target.8,49,50 Potent ligands for the Abl SH3 likewise
represent an unmet need. Despite strong homology, Abl has a
different peptide sequence preference than the Src-family
kinases; it generally exhibits >5-µM affinity for peptides that
interact with Src-family SH3 domains (Figure 2). Abl binds the
peptide p40 with 0.40-µM affinity.51 Abl also has a unique and
accessible His95 residue (homologous to Lyn 95, Figure 1). We
designed two rhodium-containing variants of the Abl-binding
peptide, p40-A1ERh and p40-Y4ERh. While p40-Y4ERh did not
improve binding, the p40-A1Rh peptide, which modeling studies
suggested is better designed to position the rhodium core near
the key His95 residue, binds Abl with 22-nM affinity, similar to
our best Src-family ligands (Table 1). As with Lyn, the p40A1Rh peptide represents the most potent ligand for the Abl SH3
domain yet reported.

Journal Name
We used catalytic protein modification to examine the
potency of the metallopeptide–Lyn interaction in a cell-like
environment. We have previously shown that rhodium
metallopeptides catalyze protein modification in lysate, with
specificity provided by molecular recognition. 52 More recent
work has demonstrated that SH3 domains are amenable to this
approach, permitting site-specific alkyne functionalization of
specific SH3 domains in lysate.53 For example, in the presence
of R5ERh metallopeptide and an alkyne–diazo reagent, the Yes
SH3 domain (expressed as a fusion with maltose-binding
protein, MBP) is readily tagged with an alkyne group, and the
modification visualized by alkyne-azide cycloaddition on a blot
membrane (Figure 5, left box).53 Because catalytic covalent
modification requires metallopeptide (R5E Rh) binding to the
Yes SH3 domain, the addition of an exogenous high-affinity
domain (Lyn, Kd = 81 nM) would be predicted to out-compete
metallopeptide binding to the substrate (Yes, Kd = 1,740 nM)
and thus to prevent modification. Indeed, when these reactions
are dosed with Lyn SH3, a drastic drop in labelling is observed,
consistent with Lyn effectively outcompeting Yes and all other
cellular proteins for the metallopeptide. Lyn itself is not
modified by the catalyst, consistent with a Lyn–metallopeptide
binding model (Figure 3b) in which both rhodium coordination
sites are blocked by histidine residues.

Figure 5. Potent sequestration of a metallopeptide catalyst by Lyn SH3. (left box)
In the absence of Lyn, a metallopeptide (R5E Rh) catalyzes covalent attachment of
an alkyne-containing small molecule to the Yes SH3 domain (expressed as a
fusion with MBP) in cell lysate, visualized after reaction with a fluorogenic
azide.53 The activity of the rhodium metallopeptide catalyst is inhibited by added
Lyn SH3, indicating selective binding in lysate. (right box) Total protein (Ponceau)
stain of the lysate reactions. Conditions: MBP-Yes fusion (2 µM), metallopeptide
(10 µM), and MBP-Yes fusion (2 µM) in E. coli lysate, diluted 2× with tertbutylhydroxylamine buffer at pH 6.2 at 4 °C.

Figure 4. ITC analysis of Abl SH3 binding to designed metallopeptides.

4 | J. Name., 2012, 00, 1-3

The potent Lyn SH3 binder we developed has functional
consequences for Lyn kinase. The SH3 domain plays many
regulatory and specificity roles for the Src family kinases in
vivo. In full-length kinase, the SH3 domain is bound to a
portion of the catalytic kinase domain, which abrogates kinase
activity. The functional consequence of ligand binding to the
SH3 domain is release of the SH3 domain from the kinase
domain and subsequent full activation of kinase activity.
Previous work indicates that SH3 interactions are necessary and
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sufficient for complete kinase activation, while SH2
interactions have a smaller effect. 5
We examined phosphorylation of a peptide substrate at low
enzyme concentration (0.074 µM) and short reaction time (t = 5
min) to minimize the alternative autophosphorylation activation
pathway (Figure 6). Kinase activation with traditional ligands
has typically required high ligand concentrations (~1 mM) to
overcome the intramolecular nature of the SH3–kinase domain
interaction. Consistent with previous results, the parent peptide,
S2E, showed slight activation only above 100 µM. Simple
rhodium complexes (Rh2(OAc)4 displayed no activation (blue
circle). However, the S2E Rh metallopeptide exhibited strong
Lyn activation at 200 nM, roughly three orders of magnitude
lower than the parent peptide. Complete activation response
was achieved at 630 nM. The only known SH3 ligand that
exhibits comparable levels of activation within the Src family is
the full-length HIV Nef protein, which binds tightly to Hck
kinase. Taken together, the kinase activation and lysate-based
inhibition demonstrate activation of the kinase target and
activity in cell-like environments, and they provide
confirmation of the potency gains made possible by rhodium
conjugates.

Figure 6. Activation of Lyn kinase activity by a metallopeptide, S2ERh, and the
parent peptide, S2E. The negative control, Rh 2(OAc)4, had no effect on kinase
activity. Full-length Lyn kinase (74 nM) was treated with substrate peptide and
ATP. Kinase activity was measured after 5 min in an adaptation of reported
methods.5 See ESI for details.

Conclusions
The S2ERh metallopeptide is the first ligand with singledigit nanomolar affinity yet reported for Lyn SH3 and is among
the very few highly potent SH3 ligands yet reported. In
addition, the S2E Rh metallopeptide is the first reported small
molecule that exhibits functional activation of Lyn kinase
activity under biologically relevant concentrations. Importantly,
an approach based on metallopeptides allows both structureguided inhibitor design and selective inhibition within
homologous protein families that are difficult to differentiate
with traditional inhibitors. By targeting unique residues at the

This journal is © The Royal Society of Chemistry 2012

ARTICLE
periphery of the binding pocket, we are able to design
specificity for Lyn, and, separately, for Lck and Hck, despite
the large sequence homology of Src-family SH3 domains. A
nanomolar Abl ligand demonstrates that the approach can be
generalized to SH3 types beyond the Src family. Rhodiumcontaining inhibitors thus should serve as powerful tools to
probe homologous protein families.
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